Guerbet Reports Revenue for 2025 and Confirms Growth Initiatives
Guerbet, a renowned leader in medical imaging solutions, unveiled revenue figures at the end of the third quarter of 2025.
Growth Indicators and Revenue Breakdown
As of September 30, 2025, Guerbet reported total revenue of €586.5 million. This figure reflects a decline of 2.8% at constant exchange rates and on a like-for-like basis, primarily due to a slump in activity within the French market. Despite this, the company has demonstrated a return to growth in Q3 2025 with a 2.6% increase in revenue driven by heightened sales of EluciremTM and strong performance on Lipiodol®.
Quarterly Performance Insights
Throughout the first nine months of the year, Guerbet experienced a steady improvement in its financial health. The first quarter saw a 7.1% drop in revenue, followed by a lesser decline of 3.9% in the second quarter. The third quarter's uptick signals optimism for the year's final quarter.
Regional Sales Performance
A closer examination of regional sales reveals varied trends:
EMEA Region
Sales in the EMEA region reached €255.8 million—a decrease of 2.3% at constant exchange rates and on a like-for-like basis. The revenue drop in France has impacted this region, as the company is still recovering from market share losses incurred during the transition from single-use to larger vials. However, during Q3, the EMEA region saw a remarkable growth of 10.2%, effectively offsetting previous losses.
Americas
The Americas reported sales of €176.5 million, down by 2.2% at constant exchange rates. The decline is attributed to pricing pressures despite a solid increase in volume, especially noticeable in Q3 where revenue fell by 5.7%, attributed to challenges at the Raleigh facility.
Asia
In Asia, revenue was recorded at €152.4 million, reflecting a 4.3% decline at constant exchange rates. Yet, the third quarter surfaced positive growth of 1.5%, with notable sales in Japan bolstering this region's recovery efforts.
Product Sector Performance
The breakdown of revenue within various product sectors highlights significant contrasts:
Diagnostic Imaging
For the first nine months, the Diagnostic Imaging division earned revenues of €508.0 million, down 4.0% but recovering stronger with a 1.7% increase in Q3. The IRM division showcased remarkable resilience with 2.0% growth at constant exchange rates, especially owing to a 9.6% jump in the recent quarter.
X-Ray Division
Conversely, the X-ray division struggled with a decrease of 7.3% at constant exchange rates. The products Xenetix®and Optiray® experienced lower demand, primarily influenced by declining activity in France.
Interventional Imaging
The Interventional Imaging division exhibited robust growth, reaching €76.7 million, corresponding to a 6.0% increase at constant exchange rates. This sector benefitted especially from the upward trend of Lipiodol®, boosted by rising volumes and prices.
Confirming Financial Targets for 2025
With an optimistic outlook, Guerbet remains confident about meeting its 2025 financial targets, forecasting a slight overall decline in revenue of around 1% at constant exchange rates. The anticipated EBITDA margin is estimated to fall between 12-13%, with free cash flow projected to remain slightly negative for the year.
As a statement of confidence, Guerbet emphasizes its commitment to innovation—dedicating 9% of its revenue towards R&D across its facilities in Europe and the United States, shaping a promising path forward.
Next Steps and Future Events
Guerbet is set to announce its full-year sales on February 5, 2026. This upcoming event will be significant to stakeholders eager to understand the company’s trajectory in financial performance amidst market challenges.
Frequently Asked Questions
What are Guerbet's recent revenue figures?
Guerbet reported total revenue of €586.5 million ending September 30, 2025, a decline of 2.8%.
When is the next financial announcement from Guerbet?
The next event is scheduled for February 5, 2026, when full-year sales will be disclosed.
How has the EMEA region performed?
The EMEA region saw sales of €255.8 million; however, Q3 experienced a growth of 10.2% following a challenging first half of the year.
What challenges did the Americas region face?
The Americas reported a decline in revenue due to pricing pressures, particularly significant in the third quarter attributed to production issues.
What are Guerbet's growth expectations for the future?
Guerbet anticipates an overall slight decline in revenue for 2025 but remains positive about their long-term growth strategy fueled by innovation and product sales.
